Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Irani

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Cancers|September 28, 2021
Adherence to Treatment Guidelines and Associated Survival in Older Patients with Prostate Cancer: A Prospective Multicentre Cohort StudyAdolfo González Serrano, Claudia Martínez Tapia, Alexandre de la Taille, et al.
Cancers|March 11, 2023
Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?Vassili Anastay, Michael Baboudjian, Alexandra Masson-Lecomte, et al.
European Urology|July 13, 2010
External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcomeMarco Auprich, Alexander Haese, Jochen Walz, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|November 15, 2021
Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapyLaure Doisy, Arnaud Cimier, Aurélien Adypagavane, et al.
World Journal of Urology|February 22, 2023
Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failureGéraldine Pignot, Michael Baboudjian, Cédric Lebacle, et al.
The Journal of Urology|December 4, 2012
Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology reviewMorgan Rouprêt, Thomas Seisen, Eva Compérat, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 23, 2005
[Urothelial tumors]Jacques Irani, Stéphane Bernardini, Jean-Louis Bonnal, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 25, 2007
[Urothelial tumors]Jacques Irani, Stéphane Bernardini, Jean-Louis Bonnal, et al.
World Journal of Urology|September 11, 2024
Efficacy and tolerance of hyperthermic intravesical chemotherapy (HIVEC) according to the number of instillations administeredPierre-Etienne Gabriel, Géraldine Pignot, Michael Baboudjian, et al.
Cancer Treatment Reviews|September 26, 2016
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literatureGwenaëlle Gravis, François Audenet, Jacques Irani, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Cancers|September 28, 2021
Adherence to Treatment Guidelines and Associated Survival in Older Patients with Prostate Cancer: A Prospective Multicentre Cohort StudyAdolfo González Serrano, Claudia Martínez Tapia, Alexandre de la Taille, et al.
Cancers|March 11, 2023
Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?Vassili Anastay, Michael Baboudjian, Alexandra Masson-Lecomte, et al.
European Urology|July 13, 2010
External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcomeMarco Auprich, Alexander Haese, Jochen Walz, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|November 15, 2021
Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapyLaure Doisy, Arnaud Cimier, Aurélien Adypagavane, et al.
World Journal of Urology|February 22, 2023
Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failureGéraldine Pignot, Michael Baboudjian, Cédric Lebacle, et al.
The Journal of Urology|December 4, 2012
Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology reviewMorgan Rouprêt, Thomas Seisen, Eva Compérat, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 23, 2005
[Urothelial tumors]Jacques Irani, Stéphane Bernardini, Jean-Louis Bonnal, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 25, 2007
[Urothelial tumors]Jacques Irani, Stéphane Bernardini, Jean-Louis Bonnal, et al.
World Journal of Urology|September 11, 2024
Efficacy and tolerance of hyperthermic intravesical chemotherapy (HIVEC) according to the number of instillations administeredPierre-Etienne Gabriel, Géraldine Pignot, Michael Baboudjian, et al.
Cancer Treatment Reviews|September 26, 2016
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literatureGwenaëlle Gravis, François Audenet, Jacques Irani, et al.
Pageof 12